Peripheral and central nervous system dysfunction, including brain injury, have been proven to develop in most of the chronic hemodialysis (HD) patients over the time. While exact pathophysiological mechanisms of brain injury in hemodialysis patients are not yet fully understood, the impairment of cerebrovascular autoregulation (CA) might be the reason. The aim of our study was to evaluate the cerebrovascular autoregulation and its dynamics during hemodialysis session, using noninvasive method, as well as to evaluate the possible association between changes of electrolyte levels and cerebrovascular autoregulation in hemodialysis patients. METHODS: Noninvasive CA monitoring of 15 HD patients was performed during the HD session by using ultrasonic monitor based on intracranial blood volume fluctuation measurement in the brain parenchyma (monitor developed at Kaunas University of Technology (Lithuania) [Ragauskas A. et al. European and US Patents N2111787B1, 2011, US7998075B2, 2009]). Pre-dialysis and post-dialysis blood samples were taken and levels of electrolytes (potassium, calcium, magnesium) and bicarbonate were analyzed. The CA status was estimated by calculating the pressure reactivity index (vPRx) as the moving correlation coefficient between slow waves of noninvasively measured arterial blood pressure and noninvasively measured slow fluctuations of intracranial blood volume. The associations between the duration of the longest CA impairment (LCAI) and changes of the level of electrolytes and bicarbonate during the HD session were analyzed. The statistical data analysis was made employing the software package of data accumulation and analysis SPSS 22.0. Spearman correlation analysis between pre-and post-dialysis variables and duration of the LCAI was done. A P value &#8804; 0.05 was considered significant. RESULTS: 9 male (60%) and 6 female (40%) HD patients were included in the study. The mean age was 58 6 10.9 years, and the mean HD vintage was 31 6 24 months. There was a negative correlation between the duration of LCAI during the HD session and post-dialysis potassium (r ¼ À0.652, P ¼ 0.006), calcium (r ¼ À0.610, P ¼ 0.016) and magnesium (r ¼ 20.23, P ¼ 0.05) levels in the blood. The post-dialysis bicarbonate level in the blood and the duration of an LCAI event during an HD session correlated directly (r ¼ 0.586, P ¼ 0.027). There were no significant associations between the duration of an LCAI and pre-dialysis laboratory values, post-dialysis sodium concentration. CONCLUSIONS: In our study, noninvasive cerebrovascular autoregulation monitoring for hemodialysis patients during the hemodialysis session was performed for the first time. The duration of the longest cerebrovascular autoregulation impairment was associated with lower post-dialysis potassium, calcium and magnesium levels in the blood and a higher bicarbonate level. 
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FP440 NOCTURNAL HOME HEMODIALYSIS WITH LOW-FLOW DIALYSATE

INTRODUCTION AND AIMS:
Nocturnal home hemodialysis (HHD) permits the flexibility of treatment in the home setting and greatly increases the cumulative number of treatment hours per week. Thus, nocturnal HHD patients may achieve much lower ultrafiltration rates and much higher solute clearance, particularly when solute clearance is largely determined by time (e.g., with phosphorus). The NxStage System One (Lawrence, Massachusetts) consumes a low volume of dialysate per session and is widely used for short daily HHD in North America and Western Europe. In this analysis, we report the results of a three-phase, prospective study of HHD patients who were converted from short daily to nocturnal treatment. METHODS: The study enrolled stable, adult patients who had been treated with short daily HHD on the NxStage System One for at least 3 months. The study comprised 3 phases: the first phase included 8 weeks of 5-6 diurnal sessions/week, at 2-4 hours/session; the second phase included 4 weeks of transition, with the goal of completing training for and achieving stability with nocturnal treatment; and the third phase included 8 weeks of 5-6 nocturnal sessions/week, at 6-10 hours/session. We analyzed the following treatment data during each phase: number of sessions/week, session length, dialysate volume, blood flow rate, and standardized Kt/V. We also assessed differences in biochemical parameters between the beginning of the first phase and the end of the third phase. RESULTS: The study enrolled 58 patients, among whom 50 (86%), 43 (74%), and 39 (67%) patients completed the first, second, and third phases. During the first and third phases, mean treatment frequency was 5.3 sessions/week, but mean (standard deviation [SD] ) session length increased from 168 (32) minutes with short daily treatment to 406 (66) minutes with nocturnal treatment (P < 0.01). Mean dialysate volume remained around 25 L/session during the first and third phases and mean (SD) blood flow rate decreased from 464 (57) to 271 (55) mL/minute with conversion from short daily to nocturnal treatment (P < 0.01). Mean (SD) standardized Kt/V increased from 2.34 (0.38) with short daily treatment to 2.64 (0.50) with nocturnal treatment (P < 0.01). Regarding changes in biochemistry, hemoglobin, ferritin, and transferrin saturation were stable. Mean (SD) serum calcium increased modestly, from 9.0 (0.8) mg/dL at the start of the first phase to 9.2 (0.6) at the end of the third phase (P ¼ 0.13), while mean serum phosphorus decreased significantly, from 5.4 mg/dL at the start of first phase to 4.8 (1.2) mg/dL at the end of the third phase (P < 0.01). The percentage of patients with serum phosphorus !5.5 mg/dL decreased during the study, as displayed in the figure. Serum intact parathyroid hormone decreased slightly during the study, but not significantly (P ¼ 0.52).
CONCLUSIONS: Nocturnal HHD with the NxStage System One is feasible with dialysate volume around 25 L/session. Nocturnal treatment delivered above-guideline urea clearance and, as predicted by kinetic modeling, reduced serum phosphorus, likely indicating that a greater mass of phosphate was removed weekly. 
FP441 HEPARIN-FREE 4 HOUR STANDARD HEMODIALYSIS SESSIONS WITH CITRIC ACIDE CONCENTRATE (CITRASATE): A SINGLE CENTRE RETROSPECTIVE COMPARATIVE STUDY WITH ANALYSIS OF THE CONFOUNDING FACTORS
INTRODUCTION AND AIMS:
Heparin-free 4 hour hemodialysis session in patients with high bleeding risk is still unresolved. Several studies suggest specific membranes or citric acid dialysate in order to reduce the heparin requirement. In this study, we assess the effect of citrate dialysate and analyze the influence of vitamin K antagonist and antiplatelet agents. The role of mechanical factors like blood flow and type of dialyzers is also analyzed which may improve success rate of heparin-free hemodialysis. METHODS: This retrospective study was performed from 1st January 2014 to 31st December 2016 in the hemodialysis center of the University hospital of Nice. The inclusion criteria were hemodialysis sessions programmed for 4 hours with citrate dialysate and bi-punctured blood circuit. We calculated the percentage of successful 4 hours (615 minutes) sessions performed with no circuit-clotting or other events leading to premature interruption of the session. The sessions were divided in three groups : group A (no-heparin) is compared to group B (2500 units) or group C (5000 units of dalteparin). Exact fisher test was used to compare categorical variables between two groups and a p-value <0.05 was considered as significant. RESULTS: During the period, 100 chronic hemodialysis patients (64 men and 36 women), with average dry body weight of 69,5 (617.3) kg ,were sorted. In total, 4924 hemodialysis sessions have been performed of which 1932 (39%) in group A, 2659 (54%) in group B and 333 (7%) in group C. The percentage of successful sessions was similar in three groups : 93.5% in group A, 92.1% (p¼0.07) in group B and 95.5% (p¼0.22) in group C. The patients taking vitamine K antagonist and Clopidogrel were similar in each group and no differences was found in patients with successful sessions. Only acetylsalicylic acid was significantly (p<0.001) different in group B in favor of successful sessions. The average flow rates were similar 357, 357 and 372 ml/min in each group with 19%, 26% and 17% of missing data respectively due to the dysfunction of computer recording box. No differences were found in favor of success rate. But we need to stratify the blood flow rate and analyze further to have more informations. The sessions were performed with 8 different types of dialyzers including low, middle and high permeability membranes. In an univariate analysis on dialyzers membrane, we did not find any preference in favor of successful 4 hour hemodialysis sessions. We didn't encounter any particular adverse effects related to citrate dialysate. The patients received adequate dialysis dose, the biological and hematological parameters were satisfactory.
CONCLUSIONS:
Our preliminary results show that citrate dialysate is safe and effective for 4-hour hemodialysis sessions and there is no supplementary benefit to intradialytic heparinization or specific costly membrane to perform a four hour hemodialysis session in high bleeding risk patients. This analysis cannot be extended to critically ill patients with high Inflammatory states and multi-visceral failure. Further studies are required to confirm this hypothesis. 
INTRODUCTION AND AIMS:
The prescription of dialysate calcium concentration (dCa) has been suggested to affect vascular calcification, but evidence is scarce. The use of citrate-acidified dialysate (dCit) may have a beneficial effect on the calcification tendency. The aim of this study was to compare the intradialytic and short-term effects of dCa of 1.50mmol/l (dCa1.50) and dCa of 1.25mmol/l (dCa.25), as well dCit (with a dCa of 1.50 mmol/l) on calcification propensity in serum. METHODS: Nineteen chronic hemodialysis patients (mean age 66.6 years) from two centers were randomized into a cross-over sequence of dCa1.25 or dCit for one week, the alternate treatment was provided after a washout week with dCa1.50. Calcification propensity of serum was assessed by time-resolved nephelometry where the T 50 reflects the transition time between formation of primary and secondary calciprotein particles. RESULTS: Intradialytic change (D) in T 50 is increased in dCit (119.6635.2min) compared to dCa1.25 (76.6640.9min, p<0.001) and dCa1.50 (62.8643.9min, p<0.001). DT50 was inversely correlated to Dphosphate in all treatments (dCa1.50: r s ¼-0.68, p<0.01; dCa1.25: r s ¼-0.69, p<0.01; dCit: r¼-0.46, p¼0.06), and to Dionized calcium in dCa1.25 (r¼-0.61, p¼0.01), dCitr (r¼-0.46, p¼0.05) and dCa1.50: r¼-0.45, p¼0.06). During the treatment week, predialysis T 50 increased significantly for dCit (278.5650.5 to 295.8655.2min, p¼0.001) with a tendency for dCa1.25 (287.6658.5 to 303.4657.9min, p¼0.07), but not for dCa 1.50 (287.0665.8 to 297.6654.9min, p¼0.47). CONCLUSIONS: Calcification propensity, as measured by the change in T 50 , improved significantly during treatment in dCit compared to dCa1.25 and dCa1.50, with effects potentially lasting beyond the dialysis treatment. Changes in ionized calcium during dialysis may also effect calcification propensity. Long term studies are needed to investigate whether dCit and modifying dCa could have a beneficial effect on patient prognosis and vascular calcification. 
The fluid transfer from the interstitial compartment into the vasculature in response to ultrafiltration is known as plasma refill rate(PRR) and it is involved in intradialytic hypotension. Subcutaneous continuous glucose monitoring(CGM) devices measure glucose concentration in the interstitial fluid. We aimed to explore if this fluid transfer influences the accuracy of the CGM device when compared with the levels of serum glucose during haemodialysis(HD) and if these differences predict the refill rate. We also intended to assess the accuracy of Hemoscan measurements as well, since it is the most used tool in terms of relative plasma change measurements. METHODS: Observational, prospective study of 13 HD sessions with consecutive paired determinations of GSM and serum glucose (before, during each hour and 20 minutes after). The plasma volume variation in the mentioned timepoints was calculated using 51 Cr-labeled erythrocytes and hematocrit by the "isotope dilution technique". We calculated relative differences (RD) between CGM and serum glucose, and PRR by subtracting absolute plasma change to ultrafiltration rate. The strength of the correlation was determined by calculating the Spearman correlation coefficient (SCC). RESULTS: Among the 13 HD sessions of 7 patients, the RD increased constantly from hour 2: -21.3%; -22.5% and -23.3% with a significant difference from the basal RD (p¼0.043; 0.036 and 0.02 respectively). This statistical significant difference was lost in the first hour and post-desconnection. However, these differences between GSM and serum glucose were not explained by PRR (p>0.05) (Figure 1) . The mean total ultrafiltration was of -2.560.82L. Refill rate was constant and did not increase along the HD session (mL): 1st hour: 4366259, 2nd: 5826299, 3rd:3786226, 4th: 4816248. Relative plasma variation measured with the Hemoscan device was compared with the isotopic method, and we found that Hemoscan underestimated the real plasma variation from hour 3 (at hour 3: -8,4% vs -19,3% and at 4 hour: -9,7% vs -24,3) (p<0.005). CONCLUSIONS: We conclude that CGM underestimated plasma glucose during HD session. Statistically higher relative differences were found from the second hour of HD, and they were lost after 20 minutes of the end of the therapy. In our experience, this phenomenon can not be explained by the plasma refilling rate. On the other hand, we showed that in our population, hemoscan measurements underrate the real plasma variation at 3rd and 4th hours, as it has been cited in previous studies.
FP444 PLASMA MOLECULAR CHANGES IN HEMODIALYSIS PATIENTS WITH POLYARYLETHERSULFONE-POLYVINYLPYRROLIDONE MEMBRANE DIALYZER (THERANOVA 400 BAXTER)
Lojze Celik
INTRODUCTION AND AIMS:
A new dialysis membrane is available to enhance middle molecule removal by dialysis. The characteristics are similar to glomeruli with high and steep cutoff for albumin without limiting the output of middle molecules and small size proteins. The aim of our study is to evaluate the reduction of a wide range of middle molecules in plasma of uremic patients undergoing standard hemodialysis with this membrane. METHODS: We studied eight stable hemodialysis patients, without acute illnesses, aged 66613 years, dry body weight 72.769.4 kg, dialytic weight loss 2.860.7 L, spKt/V Daugirdas 1.6260.25, QB 321621 ml/min, QD 531688 ml/min, session duration 233614 minutes. Plasma concentrations, before and after single bicarbonate HD sessions with Theranova (TH) and with standard polysulfone high flux dialyzers (SP), of Albumin, C Reactive Protein (CRP), Myoglobin, Interleukin 6 (IL6), Procalcitonin (PCT), Beta2-microglobulin (B2M) and vitamin B12 were measured to represent a wide range of middle molecular weight substances. The pre-post differences and percentages were calculated with correction for UF and statistically tested with nonparametric Signed Rank test for paired data.
RESULTS:
The results of the study are summarized in the two following tables: Table 2 . Plasma pre vs post dialysis percentage differences of middle molecular weight substances with Theranova (TH) and standard polysulfone (SP) bicarbonate HD. Post
